Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Ruwan ParakramaElisha FogelCarol ChandyTitto AugustineMatt CoffeyLydia TesfaSanjay GoelRadhashree MaitraPublished in: BMC cancer (2020)
Reovirus has profound immunomodulatory properties that span the genomic, protein and immune cell distribution levels. This is the first study with reovirus in cancer patients that demonstrates these multi- layered effects, demonstrating how reovirus can function as an immune stimulant (augmenting the efficacy of immuno-chemo-therapeutic drugs), and an oncolytic agent. Reovirus thus functions bimodally as an oncolytic agent causing lysis of tumor cells, and facilitator of immune-mediated recognition and destruction of tumor cells.
Keyphrases
- metastatic colorectal cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- photodynamic therapy
- intellectual disability
- squamous cell carcinoma
- cancer therapy
- gene expression
- protein protein
- locally advanced
- autism spectrum disorder
- patient reported
- reduced graphene oxide
- radiation therapy